ReviewOpen access rheumatology : research and reviews2016
Adult-onset Still's disease: current challenges and future prospects.
Review in Open access rheumatology : research and reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Bibliometrics analysis on the research status and trends of adult-onset Still's disease: 1921-2021.Frontiers in immunology · 2022Pooled it
- When Fever Defies Diagnosis: Wissler-Fanconi Syndrome as an Atypical Presentation of Adult-Onset Still's Disease.Clinical case reports · 2026Article
- Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still's disease: a single-center retrospective study.Frontiers in immunology · 2026Article
- Advancing Precision Medicine in Adult-Onset Still's Disease: Insights into Biomarkers, Therapies, and COVID-19 Impacts.Mediterranean journal of rheumatology · 2025Review
- Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still's disease: a multicenter Spanish study.Rheumatology international · 2024Article
- Adult-onset Still's disease and fever of unknown origin in India.Clinical and experimental medicine · 2023Article
- Successful Treatment of Recurrent Adult-Onset Still's Disease with Tocilizumab: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2023Article
- Adult-onset Still's disease after environmental exposure while working in Africa.BMJ case reports · 2021Article
- Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis.Clinical rheumatology · 2020Article
- Article
- Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.Chinese medical journal · 2019Review
- Paving a Shorter Path Towards Diagnosis: A Case on Adult Onset Still's Disease from Pakistan.Cureus · 2018Article
- Acute appendicitis complicated with necrotizing fasciitis in a patient with adult-onset Still's disease: A case report.Medicine · 2018Article
- Cardiovascular disease in patients with autoinflammatory syndromes.Rheumatology international · 2018Review
- Quotidian High Spiking Fevers in Adult Still's Disease.The American journal of case reports · 2017Article
- [Myocardiopericarditis in adult still's disease].Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult-onset Still's disease (AOSD) - a multi-systemic inflammatory condition characterized by high fevers, polyarthritis, an evanescent rash, and pharyngitis - has been a challenging condition to diagnose expediently and treat effectively. Questions remain regarding the underlying pathophysiology and etiology of AOSD. Pathognomonic diagnostic tests and reliable biomarkers remain undiscovered. Over the past decade, important progress has been made. Diagnostic criteria employing glycosylated ferritin have improved specificity. More important, novel biologic therapies have offered important clues to AOSD's underlying pathophysiology. Cytokine-specific biologic therapies have been instrumental in providing more effective treatment for disease refractory to conventional treatment. While IL-1 therapy has demonstrated efficacy in refractory disease, novel therapies targeting IL-6 and IL-18 show great promise and are currently under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.